EP3239173A3 - Biomarkertest für die pathologie - Google Patents

Biomarkertest für die pathologie Download PDF

Info

Publication number
EP3239173A3
EP3239173A3 EP17172678.9A EP17172678A EP3239173A3 EP 3239173 A3 EP3239173 A3 EP 3239173A3 EP 17172678 A EP17172678 A EP 17172678A EP 3239173 A3 EP3239173 A3 EP 3239173A3
Authority
EP
European Patent Office
Prior art keywords
collagen type
neo
measure
protein
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17172678.9A
Other languages
English (en)
French (fr)
Other versions
EP3239173A2 (de
Inventor
Sanne Skovgård VEIDAL
Morten Asser Karsdal
Diana J. Leeming
Natasha Barascuk
Helene Skjot-Arkil
Efstathios Vassiliadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordic Bioscience AS
Original Assignee
Nordic Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Bioscience AS filed Critical Nordic Bioscience AS
Priority to EP19188754.6A priority Critical patent/EP3590959A3/de
Publication of EP3239173A2 publication Critical patent/EP3239173A2/de
Publication of EP3239173A3 publication Critical patent/EP3239173A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP17172678.9A 2011-07-20 2012-07-18 Biomarkertest für die pathologie Withdrawn EP3239173A3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19188754.6A EP3590959A3 (de) 2011-07-20 2012-07-18 Biomarkertest für die pathologie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/187,205 US9404932B2 (en) 2007-11-05 2011-07-20 Pathology biomarker assay
EP12740115.6A EP2734542B1 (de) 2011-07-20 2012-07-18 Pathologischer biomarkertest

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP12740115.6A Division EP2734542B1 (de) 2011-07-20 2012-07-18 Pathologischer biomarkertest
EP12740115.6A Division-Into EP2734542B1 (de) 2011-07-20 2012-07-18 Pathologischer biomarkertest

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19188754.6A Division EP3590959A3 (de) 2011-07-20 2012-07-18 Biomarkertest für die pathologie

Publications (2)

Publication Number Publication Date
EP3239173A2 EP3239173A2 (de) 2017-11-01
EP3239173A3 true EP3239173A3 (de) 2018-01-24

Family

ID=46581944

Family Applications (3)

Application Number Title Priority Date Filing Date
EP12740115.6A Not-in-force EP2734542B1 (de) 2011-07-20 2012-07-18 Pathologischer biomarkertest
EP19188754.6A Withdrawn EP3590959A3 (de) 2011-07-20 2012-07-18 Biomarkertest für die pathologie
EP17172678.9A Withdrawn EP3239173A3 (de) 2011-07-20 2012-07-18 Biomarkertest für die pathologie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP12740115.6A Not-in-force EP2734542B1 (de) 2011-07-20 2012-07-18 Pathologischer biomarkertest
EP19188754.6A Withdrawn EP3590959A3 (de) 2011-07-20 2012-07-18 Biomarkertest für die pathologie

Country Status (6)

Country Link
US (1) US9404932B2 (de)
EP (3) EP2734542B1 (de)
JP (3) JP6162115B2 (de)
DK (1) DK2734542T3 (de)
ES (1) ES2708424T3 (de)
WO (1) WO2013011056A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897492T3 (es) * 2007-11-05 2022-03-01 Nordic Bioscience Imaging As Marcadores bioquímicos para la evaluación de riesgos de CVD
EP2770327B1 (de) * 2009-03-30 2017-06-14 Nordic Bioscience A/S Fibrosebiomarkertest
GB201107922D0 (en) * 2011-05-12 2011-06-22 Nordic Bioscience As Biochemical markers for CVD risk assessment
GB201307387D0 (en) 2013-04-24 2013-06-05 Nordic Bioscience As Collegen type VI alpha-1 assay
WO2016138522A1 (en) * 2015-02-27 2016-09-01 Aurora Health Care, Inc. Systems and methods for identifying patients at risk for a cardiovascular condition
GB201615746D0 (en) * 2016-09-15 2016-11-02 Nordic Bioscience As Nidogen-1 Assay
JP2019013543A (ja) * 2017-07-07 2019-01-31 株式会社三洋物産 遊技機
GB201712071D0 (en) * 2017-07-27 2017-09-13 Nordic Bioscience As Collagen type X alpha-1 assay
CA3087305A1 (en) 2017-12-13 2019-06-20 Glx Analytix Aps Biomarkers for multiple sclerosis
GB201802070D0 (en) * 2018-02-08 2018-03-28 Nordic Bioscience As Elastin assay
RU2706541C1 (ru) * 2018-12-27 2019-11-19 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ оценки качества предоперационной подготовки у больных с дисплазией соединительной ткани
JP7547350B2 (ja) 2019-01-22 2024-09-09 クレムソン・ユニバーシティ・リサーチ・ファウンデーション 抗エラスチン抗体及び使用方法
WO2020218465A1 (ja) * 2019-04-26 2020-10-29 中外製薬株式会社 子宮内膜症の診断方法、病態モニタリング方法及びキット
EP3980785A1 (de) * 2019-06-05 2022-04-13 Nordic Bioscience A/S Test zur beurteilung von herzversagen
GB201917819D0 (en) * 2019-12-05 2020-01-22 Nordic Bioscience As A neo-epitope specific assay measuring protease mediated degradation of type iv collagen
US20240003906A1 (en) * 2020-04-16 2024-01-04 Nordic Bioscience A/S Biomarker of Fibrosis
SE2150815A1 (en) * 2021-06-23 2022-12-24 SGPTH Life Science AB Biglycan peptide and antibodies
CN113388005B (zh) * 2021-06-30 2022-09-27 北京泽勤生物医药有限公司 增强成骨细胞活性的多肽及其在治疗骨科疾病中的应用
CN115166256B (zh) * 2022-06-16 2025-07-18 郑州大学第一附属医院 胶原蛋白中氨基酸位点修饰在胰腺癌检测中的应用
GB202209866D0 (en) * 2022-07-05 2022-08-17 Nordic Bioscience As Cross linked collagen type v assay
CN117343132B (zh) * 2023-09-25 2024-03-12 山东省农业科学院 一种三文鱼鱼皮来源的ace抑制肽及制备方法
CN120290673A (zh) * 2025-04-02 2025-07-11 湖北省农业科学院农产品加工与核农技术研究所 一种抗光老化胶原多肽的制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059972A2 (en) * 2007-11-05 2009-05-14 Nordic Bioscience A/S Biochemical markers for cvd risk assessment
WO2010031822A1 (de) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Nierenzellkarzinom
WO2010079076A2 (de) * 2008-12-17 2010-07-15 Mosaiques Diagnostics And Therapeutics Ag Autosomal dominante polyzystische nierenerkrankung (adpkd)
US20100209940A1 (en) * 2007-11-05 2010-08-19 Nordic Bioscience A/S Fibrosis biomarker assay
WO2011029954A2 (de) * 2009-09-14 2011-03-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US5387504A (en) 1992-09-30 1995-02-07 Merck & Co., Inc. Monospecific antibodies and assay system for detecting stromelysin cleavage products
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
EP0696597B1 (de) * 1994-08-11 2008-03-26 Sanofi-Aventis Deutschland GmbH Monoklonale Antikörper zur selektiven immunologischen Bestimmung von hochmolekularen, intakten Lamininformen in Körperflüssigkeiten
US6060255A (en) 1997-10-03 2000-05-09 Tosoh Corporation Type IV collagen high molecular form and production and diagnostic use thereof
EP0913692A1 (de) 1997-10-31 1999-05-06 Bayer Ag Immunassay zum Nachweis von prokollagen-III-C-terminalen Propeptid
WO1999061477A2 (en) 1998-05-28 1999-12-02 Bayer Aktiengesellschaft Monoclonal antibody and assay for detecting piiinp
JP2002065283A (ja) 2000-06-12 2002-03-05 Wako Pure Chem Ind Ltd ハイブリッド酵素およびその用途
CA2420089C (en) 2000-08-21 2009-04-14 Assistance Publique-Hopitaux De Paris Diagnosis method of fibrotic disease using biochemical markers
EP1384079A2 (de) 2001-05-02 2004-01-28 Oxford GlycoSciences (UK) Limited Proteinen, genen und ihre verwendung zur diagnose und behandlung von brustkrebs
US20050255491A1 (en) 2003-11-13 2005-11-17 Lee Frank D Small molecule and peptide arrays and uses thereof
US20060154318A1 (en) 2004-06-09 2006-07-13 Anderson Norman L Stable isotope labeled polypeptide standards for protein quantitation
EP1676602A1 (de) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Kontinuierlicheverabreichung von Epitope aus dem atherosklerotischem Belag zur Behandlung von Atheriosklerose
EP1948686A4 (de) 2005-10-26 2009-06-10 Stc Unm C-reaktives protein und dessen verwendung zur behandlung von systemischem lupuserythematodes und verwandten leiden
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
CN103336129A (zh) * 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
DE102007053916A1 (de) 2007-11-09 2009-05-14 Deutsche Thomson Ohg Verfahren zum Verwalten von Netzkomponenten in einem Netzwerk und Netzkomponente
CN102203617A (zh) * 2008-10-22 2011-09-28 生物标记设计研究有限责任公司 用于检测和诊断骨或软骨障碍的方法
CA2757444A1 (en) * 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
EP2478923B1 (de) * 2009-09-04 2016-05-04 FUJIFILM Corporation Ein knochenregenerierungsmittel, das gelatine umfasst

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059972A2 (en) * 2007-11-05 2009-05-14 Nordic Bioscience A/S Biochemical markers for cvd risk assessment
US20100209940A1 (en) * 2007-11-05 2010-08-19 Nordic Bioscience A/S Fibrosis biomarker assay
WO2010031822A1 (de) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Nierenzellkarzinom
WO2010079076A2 (de) * 2008-12-17 2010-07-15 Mosaiques Diagnostics And Therapeutics Ag Autosomal dominante polyzystische nierenerkrankung (adpkd)
WO2010115749A2 (en) * 2009-03-30 2010-10-14 Nordic Bioscience A/S Fibrosis biomarker assay
WO2011029954A2 (de) * 2009-09-14 2011-03-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTIANSEN ET AL: "Effect of fibroblast activation protein and @a"2-antiplasmin cleaving enzyme on collagen Types I, III, and IV", ARCHIVES OF BIOCHEMISTRY AND BIOPHY, ACADEMIC PRESS, US, vol. 457, no. 2, 9 January 2007 (2007-01-09), pages 177 - 186, XP005762561, ISSN: 0003-9861, DOI: 10.1016/J.ABB.2006.11.006 *

Also Published As

Publication number Publication date
WO2013011056A2 (en) 2013-01-24
JP6162115B2 (ja) 2017-07-12
WO2013011056A3 (en) 2013-03-14
US9404932B2 (en) 2016-08-02
JP6706297B2 (ja) 2020-06-03
ES2708424T3 (es) 2019-04-09
DK2734542T3 (en) 2019-02-18
US20120045781A1 (en) 2012-02-23
JP6408051B2 (ja) 2018-10-17
JP2014521098A (ja) 2014-08-25
JP2017134079A (ja) 2017-08-03
JP2019007978A (ja) 2019-01-17
EP3590959A3 (de) 2020-04-08
EP3239173A2 (de) 2017-11-01
EP2734542A2 (de) 2014-05-28
EP3590959A2 (de) 2020-01-08
EP2734542B1 (de) 2018-12-26

Similar Documents

Publication Publication Date Title
EP3239173A3 (de) Biomarkertest für die pathologie
WO2010115749A3 (en) Fibrosis biomarker assay
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009059972A3 (en) Biochemical markers for cvd risk assessment
EP2829881A3 (de) Diagnosemittel für Darmkrebs
WO2009143098A3 (en) Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
WO2012175741A3 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2010021822A3 (en) Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
EP3156925A3 (de) Copd-biomarkersignaturen
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
JP2012522233A5 (de)
IN2014CN01787A (de)
NZ599105A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
NZ606687A (en) Ratio based biomarkers and methods of use thereof
EP4335932A3 (de) Verfahren zur überwachung von zuständen durch sequenzanalyse
WO2010148391A3 (en) Biomarker assay of neurological condition
SG195180A1 (en) Method for detecting disease biomarkers
EP3029153A3 (de) Biomarker für mesotheliome und verwendungen davon
WO2014144129A3 (en) Biomarkers and methods for predicting preterm birth
EA201290311A1 (ru) Факторы риска и прогнозирование инфаркта миокарда
EP3293522A3 (de) Lipidomik-biomarker zur identifizierung von patienten mit hohem risiko einer koronararterienerkrankung
ES2974622T3 (es) Procedimiento de diagnóstico de las cualidades estéticas de la piel
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
EP2577307A4 (de) Diagnose-assay

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2734542

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VEIDAL, SANNE, SKOVGARD

Inventor name: SKJOT-ARKIL, HELENE

Inventor name: VASSILIADIS, EFSTATHIOS

Inventor name: LEEMING, DIANA J.

Inventor name: BARASCUK, NATASHA

Inventor name: KARSDAL, MORTEN ASSER

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/00 20060101ALI20171221BHEP

Ipc: C07K 14/78 20060101AFI20171221BHEP

Ipc: G01N 33/68 20060101ALI20171221BHEP

Ipc: G01N 33/53 20060101ALI20171221BHEP

17P Request for examination filed

Effective date: 20180221

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17Q First examination report despatched

Effective date: 20190131

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190813